Neuromyelitis Optica Spectrum Disorder Clinical Trial
Official title:
A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.
n/a
| NCT number | NCT05199688 |
| Study type | Interventional |
| Source | Hoffmann-La Roche |
| Contact | Reference Study ID Number: WN41733 https://forpatients.roche.com |
| Phone | 888-662-6728 (U.S.) |
| [email protected] | |
| Status | Not yet recruiting |
| Phase | Phase 3 |
| Start date | May 26, 2022 |
| Completion date | February 28, 2027 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT03002038 -
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04064944 -
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
|
Phase 2 | |
| Completed |
NCT01845584 -
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
|
Phase 2 | |
| Active, not recruiting |
NCT04660539 -
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 3 | |
| Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 | |
| Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|
||
| Completed |
NCT01500681 -
Maintenance Plasma Exchange for Neuromyelitis Optica
|
||
| Not yet recruiting |
NCT05346354 -
Phase 2/3 Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
|
Phase 2/Phase 3 | |
| Completed |
NCT02003144 -
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
|
Phase 3 | |
| Completed |
NCT02276963 -
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
|
Phase 1 | |
| Recruiting |
NCT04155424 -
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
|
Phase 2/Phase 3 | |
| Completed |
NCT03819413 -
Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital
|
||
| Completed |
NCT02893111 -
Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
|
Phase 2 | |
| Active, not recruiting |
NCT04201262 -
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
|
Phase 3 | |
| Withdrawn |
NCT03605238 -
Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20
|
Phase 1 | |
| Recruiting |
NCT03900221 -
French Registry for Monitoring Pregnancies for Multiple Sclerosis
|
||
| Completed |
NCT03138421 -
Central Pain Study for ABX-1431
|
Phase 1 | |
| Not yet recruiting |
NCT05269667 -
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
|
Phase 4 | |
| Enrolling by invitation |
NCT04886492 -
CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
|